High Insider Ownership Growth Companies On SEHK In June 2024

Amidst a backdrop of fluctuating global markets, Hong Kong's Hang Seng Index has shown resilience with a modest gain, reflecting investor optimism and robust retail sales growth. In such an environment, stocks with high insider ownership in Hong Kong can be particularly compelling as they often signal strong confidence from those closest to the company's operations.

Top 10 Growth Companies With High Insider Ownership In Hong Kong

Name	Insider Ownership	Earnings Growth
iDreamSky Technology Holdings (SEHK:1119)	20.1%	104.1%
Fenbi (SEHK:2469)	32.5%	43%
Zylox-Tonbridge Medical Technology (SEHK:2190)	18.7%	79.3%
Adicon Holdings (SEHK:9860)	22.3%	29.6%
Tian Tu Capital (SEHK:1973)	33.9%	70.5%
DPC Dash (SEHK:1405)	38.2%	89.7%
Biocytogen Pharmaceuticals (Beijing) (SEHK:2315)	13.9%	100.1%
Zhejiang Leapmotor Technology (SEHK:9863)	15%	76.5%
Beijing Airdoc Technology (SEHK:2251)	28.2%	83.9%
Ocumension Therapeutics (SEHK:1477)	23.1%	93.7%

Click here to see the full list of 53 stocks from our Fast Growing SEHK Companies With High Insider Ownership screener.

We'll examine a selection from our screener results.

BYD

Simply Wall St Growth Rating: ★★★★☆☆

Overview: BYD Company Limited operates in the automobile and battery sectors across Mainland China, Hong Kong, Macau, Taiwan, and internationally, with a market capitalization of approximately HK$745.91 billion.

Operations: The company's revenue is primarily generated from its automobile and battery sectors across various regions including Mainland China, Hong Kong, Macau, Taiwan, and internationally.

Insider Ownership: 30.1%

Earnings Growth Forecast: 14.9% p.a.

BYD, a notable growth company in Hong Kong, demonstrates robust insider ownership but shows mixed financial dynamics. Its earnings grew by 52.7% last year and are projected to increase at 14.9% annually, surpassing the local market's average of 11.5%. However, its revenue growth forecast of 14.1% yearly slightly lags behind more aggressive benchmarks considered high growth. Despite trading below fair value by 14.4%, indicating potential undervaluation, the absence of significant insider buying over recent months might temper investor enthusiasm regarding governance and future prospects alignment.

• Dive into the specifics of BYD here with our thorough growth forecast report.

• Our valuation report here indicates BYD may be overvalued.

SEHK:1211 Earnings and Revenue Growth as at Jun 2024

Meitu

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Meitu, Inc. is an investment holding company that specializes in creating image, video, and design products aimed at enhancing digitalization in the beauty industry, operating both in the People’s Republic of China and internationally, with a market capitalization of HK$12.11 billion.

Operations: The company generates revenue primarily through its Internet Business segment, which amounted to CN¥2.70 billion.

Insider Ownership: 36.6%

Earnings Growth Forecast: 28.9% p.a.

Meitu, a growth-oriented company in Hong Kong, recently approved significant corporate governance changes and dividend payouts at its AGM. While Meitu's revenue growth is expected to be robust at 17.7% annually, slightly below the high-growth benchmark of 20%, its earnings are projected to expand impressively by 28.9% per year, outpacing the local market's average. Despite trading significantly below its estimated fair value, concerns about shareholder dilution and substantial insider selling could affect investor confidence in its governance alignment.

• Navigate through the intricacies of Meitu with our comprehensive analyst estimates report here.

• In light of our recent valuation report, it seems possible that Meitu is trading beyond its estimated value.

SEHK:1357 Earnings and Revenue Growth as at Jun 2024

Ocumension Therapeutics

Simply Wall St Growth Rating: ★★★★★☆

Overview: Ocumension Therapeutics operates as an ophthalmic pharmaceutical platform company in the People's Republic of China, with a market capitalization of approximately HK$4.74 billion.

Operations: The company generates revenue primarily through the discovery, development, and commercialization of ophthalmic therapies, totaling CN¥246.37 million.

Insider Ownership: 23.1%

Earnings Growth Forecast: 93.7% p.a.

Ocumension Therapeutics, a Hong Kong-based growth company with high insider ownership, has shown promising developments in its pharmaceutical pipeline. Recent successful phase III trials of OT-502 and OT-702 highlight its innovation in ophthalmic treatments. Despite a low forecasted return on equity of 3.8% in three years, revenue and earnings are expected to grow by 35.2% and 93.7% annually. These factors position Ocumension as an emerging leader in its sector, although profitability is only anticipated within the next three years.

• Get an in-depth perspective on Ocumension Therapeutics' performance by reading our analyst estimates report here.

• Insights from our recent valuation report point to the potential overvaluation of Ocumension Therapeutics shares in the market.

SEHK:1477 Earnings and Revenue Growth as at Jun 2024

Taking Advantage

• Gain an insight into the universe of 53 Fast Growing SEHK Companies With High Insider Ownership by clicking here.

• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.

• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include SEHK:1211 SEHK:1357 and SEHK:1477.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com